Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - Kura Oncology, Inc. will report its fourth quarter and full year 2025 financial results on March 5, 2026, before U.S. markets open, followed by a conference call and webcast for discussion [1]. Company Overview - Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [3]. - The company has developed KOMZIFTI™, an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and is advancing research in menin inhibition and farnesyl transferase inhibition [3].